Latest Breaking News On - Product revenue increased - Page 1 : comparemela.com

Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Calendar Year 2023.

United statesSouth koreaHainan provinceCh ungch ong buktoFosun pharmaCarl spanaSecurities exchangeExchange commissionPalatin technologies incPrnewswire palatin technologies incKwangdong pharmaceuticalsEnrollment completeDry eye diseaseData currently expected lateCalendar yearUlcerative colitis

Transphorm Announces Fiscal 2024 Second Quarter Results and Provides Business Update

- Reports Second Quarter Year-Over-Year Revenue Grew 37% to $5.0 Million as Gross Margin Increased by 11.5% to 23% - Product Revenue Increased to $3.55 Million,

United statesCameron mcaulayJack perkinsPrimit parikhCompany to host webcastExchange commissionYsolar co ltdCompany gaUnited states securities exchangeTransphorm incCompany contactBofa securities incAnhui daheng new energy technology coStrategic communicationsGross margin increasedProduct revenue increased

Palatin Technologies, Inc : Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update

Palatin Technologies, Inc : Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCh ungch ong buktoSouth koreaNew jerseyHainan provinceBaden wübergFosun pharmaCarl spanaSecurities exchangeKwangdong pharmaceuticalsPalatin technologies incPrnewswire palatin technologies incExchange commissionDry eye diseaseData expected lateCalendar year

Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update

Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023.

United statesCh ungch ong buktoSouth koreaNew jerseyHainan provinceCarl spanaFosun pharmaPalatin technologies incKwangdong pharmaceuticalsSecurities exchangePrnewswire palatin technologies incDry eye diseaseData expected lateCalendar yearClinical efficacy across multiple signsDry eye

Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event Analysis of Lead-In Population of Initial 120 Patients Showed Statistical.

United statesNew jerseyCarl spanaPrnewswire palatin technologies incSecurities exchangeJersey economic development authorityPalatin technologies incDilutive funding through nj economic development programJersey technology business tax certificate transfer programAssociation of researchInternational journal of molecular sciencesDry eye disease presentedLead in populationShowed statistical separationClinical efficacy across multiple signsDry eye